Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review-Reference-Cited by-同舟云学术

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review

Published:2022-05-16 Issue:9 Volume:5 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Ueno Masayuki¹²^ORCID,Takabatake Hiroyuki¹,Hata Ayako¹,Kayahara Takahisa¹,Morimoto Youichi¹,Notohara Kenji³,Mizuno Motowo¹

Affiliation:

1. Department of Gastroenterology and Hepatology Kurashiki Central Hospital Okayama Japan

2. Department of Gastroenterology and Hepatology, Graduate School of Medicine Kyoto University Kyoto Japan

3. Department of Anatomic Pathology Kurashiki Central Hospital Okayama Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1624

Reference33 articles.

1. Immune Checkpoint Blockade in Cancer Therapy

3. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells

5. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review;Molecular Biology Reports;2024-07-31

2. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids;Journal for ImmunoTherapy of Cancer;2024-07

3. From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events;Asia Pacific Allergy;2024-05-30

4. Effective treatment of steroid‐resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil;Respirology Case Reports;2024-04

5. Corticosteroid-resistant immune-related adverse events: a systematic review;Journal for ImmunoTherapy of Cancer;2024-01